1. Search Result
Search Result
Results for "

serotype

" in MedChemExpress (MCE) Product Catalog:

31

Inhibitors & Agonists

7

Biochemical Assay Reagents

3

Peptides

1

Inhibitory Antibodies

5

Natural
Products

9

Recombinant Proteins

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99214

    KBPA101

    Bacterial Infection
    Panobacumab (KBPA101) is a fully human IgM/κ monoclonal antibody generated by immortalizing human B lymphocytes against the LPS O polysaccharide of serotype O11 of P. aeruginosa .
    Panobacumab
  • HY-106161
    Rupintrivir
    5 Publications Verification

    AG7088

    Virus Protease Enterovirus Infection Inflammation/Immunology
    Rupintrivirvr (AG7088), an antiviral agent, is a potent, selective and irreversible inhibitor of human rhinovirus (HRV) 3C protease. Rupintrivirvr inhibits replication of a panel of 48 different HRV serotypes in H1-HeLA and MRC-5 cell protection assays, with a mean EC50 of 0.023 μM. Rupintrivirvr shows immune-modulatory effect .
    Rupintrivir
  • HY-12349

    Others Infection
    H1PVAT is a potent and selective inhibitor of poliovirus serotypes (PV-1, PV-2, PV-3), and inhibits early stage of the replication. H1PVAT interacts with viral capsid directly and protects PV against heat inactivation .
    H1PVAT
  • HY-D1056C1

    LPS, from Salmonella enterica (serotype enteritidis)

    Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from S. enterica serotype enteritidis is a lipopolysaccharide endotoxin that causes gastrointestinal disease in humans and can be transmitted through contaminated eggs or foods based on eggs and poultry meat products. S. enterica serotype enteritidis is capable of producing high molecular weight LPS-O antigen chains, Lipopolysaccharides, from S. enterica serotype typhimurium (HY-D1056C3) did not. S. enterica serotype enteritidis is similar to other pathogenic Salmonella. Lipopolysaccharides, from S. enterica serotype enteritidis' O antigen is associated with phage attachment in the early stages of phage infection S. Enteritidis .
    Lipopolysaccharides, from S. enterica serotype enteritidis
  • HY-D1056C4

    LPS, from Salmonella enterica (serotype abortus equi)

    Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides are lipopolysaccharide endotoxins and TLR-4 activators that activate pathogenicity-associated molecular patterns (PAMPs) of the immune system and induce cell secretion of migrasomes. Lipopolysaccharides can be extracted from the outer leaflet of the outer membrane of Gram-negative bacteria and are composed of an antigenic O-specific chain, a core oligosaccharide, and lipid A. Lipopolysaccharides (LPS), from S. enterica serotype abortus equi is a kind of endotoxins derived from S. enterica serotype abortus equi .
    Lipopolysaccharides, from S. enterica serotype abortus equi
  • HY-D1056C2

    LPS, from Salmonella enterica (serotype minnesota)

    Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides (LPS) are specific endotoxins and one of the major components of the cell wall of Gram-negative bacteria. Lipopolysaccharides consist of three parts: lipid A, core oligosaccharide, and O-specific polysaccharide. Lipopolysaccharides are powerful immune stimulants that can activate the host immune system, particularly by binding to Toll-like receptor 4 (TLR4) on the surface of immune cells, triggering an inflammatory response. The LPS of most Salmonella serotypes has a complex O-antigen (OAg) structure, with the number of OAg units in the core polysaccharide varying between 16 and over 100 repeats. Mutations in OAg-regulating factors that alter the OAg structure can change the interaction between Salmonella and epithelial cells. Strains with long OAg have increased SPI1-T3SS effector protein translocation and invasion. Strains completely lacking OAg exhibit increased invasiveness and higher adhesiveness. This product is derived from Salmonella enterica serotype Minnesota. Lipopolysaccharides, from S. enterica serotype minnesota, can be used to study host immune system activation and its role in inflammation and immune regulation .
    Lipopolysaccharides, from S. enterica serotype minnesota
  • HY-126843

    Biochemical Assay Reagents Infection
    Chromozym U is a chromogenic agent that can be used for detection of urokinase in Shigella. Chromozym U is capable of differentiating serotypes of Shigella dysenteriae, Shigella flexneri, Shigella boydii .
    Chromozym U
  • HY-W596782

    Chaetochromin

    Others Neurological Disease
    Chaetochromin A (Compound 1) is a fungal metabolite. Chaetochromin A shows inhibitory effect on botulinum neurotoxin serotype A (BoNT A) (IC50= 24.6 μM) .
    Chaetochromin A
  • HY-138061

    Flavivirus Dengue virus DNA/RNA Synthesis Infection
    DENV-IN-2 is a potent dengue viral replication inhibitor extracted from patent WO2018215315A1, compound 6AB, has an EC50 of 0.016 nM. DENV-IN-2 shows high potent activity against all four serotypes of the Dengue virus with EC50s ranging from 0.013 to 0.029 nM .
    DENV-IN-2
  • HY-D1056C3

    LPS, from Salmonella enterica (serotype typhimurium)

    Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from S. enterica serotype typhimurium, are a kind of lipid-polysaccharide endotoxin. Smooth Gram-negative bacteria's lipopolysaccharides are made up of three components: lipid A, core oligosaccharide, and O antigen (OAg). The O antigen is a polymer of sugar repeat units (RUs); the Wzz protein regulates the length of the O antigen in lipopolysaccharides, and the number of RUs attached to lipid A is determined by the modal value set by the Wzz protein. S. enterica typhimurium has two Wzz proteins: WzzST (which makes the modal range of the O antigen between 16 and 35 RUs) and WzzfepE (which makes the modal value over 100 RUs). Mutating the genes corresponding to these two proteins causes the formation of short-chain O antigen chains and significantly reduces bacterial pathogenicity .
    Lipopolysaccharides, from S. enterica serotype typhimurium
  • HY-13637
    Ganciclovir
    15+ Cited Publications

    BW 759; 2'-Nor-2'-deoxyguanosine

    CMV HSV Antibiotic Nucleoside Antimetabolite/Analog Infection Cancer
    Ganciclovir (BW 759), a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovir also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir has an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1) and can diffuse into the brain .
    Ganciclovir
  • HY-13637A
    Ganciclovir sodium
    15+ Cited Publications

    BW 759 sodium; 2'-Nor-2'-deoxyguanosine sodium

    CMV HSV Antibiotic Nucleoside Antimetabolite/Analog Infection Cancer
    Ganciclovir (BW 759) sodium, a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovir sodium also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir sodium inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir sodium has an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1) and can diffuse into the brain .
    Ganciclovir sodium
  • HY-13637B

    BW-759 hydrate; 2'-Nor-2'-deoxyguanosine hydrate

    CMV HSV Antibiotic Nucleoside Antimetabolite/Analog Infection Cancer
    Ganciclovir (BW 759) hydrate, a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovir hydrate also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir hydrate inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir hydrate has an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1) and can diffuse into the brain .
    Ganciclovir hydrate
  • HY-13637R

    CMV HSV Antibiotic Nucleoside Antimetabolite/Analog Infection Cancer
    Ganciclovir (Standard) is the analytical standard of Ganciclovir. This product is intended for research and analytical applications. Ganciclovir (BW 759), a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovir also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir has an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1) and can diffuse into the brain .
    Ganciclovir (Standard)
  • HY-U00265

    3-Carbethoxypsoralen; 3-Ethoxycarbonylpsoralen

    Others Infection
    3-CPs is a serotype capsular polysaccharide which can interfere with antibody-mediated bacterial killing.
    3-CPs
  • HY-113714

    Others Infection
    C562-1101 is a small molecule potent botulinum neurotoxins E serotype (BoNT/E) inhibitor .
    C562-1101
  • HY-N11096

    Flavivirus Dengue virus Infection Cancer
    Sinococuline is a potent anti-dengue agent that is effective against all four serotypes of dengue virus (DENV). Sinococuline is also an effective tumor cell growth inhibitor .
    Sinococuline
  • HY-138543

    Flavivirus Dengue virus Virus Protease Infection
    NITD-688 is an orally active pan-serotype inhibitor of the dengue virus NS4B protein. NITD-688 can be used in the research of dengue virus (DENV) .
    NITD-688
  • HY-153810

    JNJ-1802

    Virus Protease Flavivirus Dengue virus Infection
    Mosnodenvir (JNJ-1802) is an orally active pan serotype dengue virus (DENV) inhibitor, with EC50 values ranging from 0.057 to 11 nM for four dengue virus (DENV) serotypes. Mosnodenvir blocks viral replication by inhibiting the formation of complexes between two viral proteins, nonstructural protein 3 (NS3) and NS4B, thereby preventing the formation of new viral RNA. Mosnodenvir exhibits picomolar to nanomolar antiviral activity in vitro and has antiviral efficacy in mice and non-human primates .
    Mosnodenvir
  • HY-13784
    Pirodavir
    3 Publications Verification

    R77975

    Enterovirus Infection
    Pirodavir is a potent, broad-spectrum picornavirus inhibitor, and is highly active against both group A and group B rhinovirus serotypes.Pirodavir is very potent in a virus yield reduction assay (IC90=2.3 nM).
    Pirodavir
  • HY-149251

    Flavivirus Dengue virus Infection
    DENV-IN-10 is a potent tetravalent dengue inhibitor, with EC50s of 1.36, 0.87, 0.94, and 0.95 μM against DENV-1-4 serotypes, respectively. DENV-IN-10 is a post-entry replication inhibitor that appears to be specific for cells of primate origin .
    DENV-IN-10
  • HY-B1030
    Lanatoside C
    4 Publications Verification

    Flavivirus Dengue virus Autophagy Enterovirus Cardiovascular Disease Cancer
    Lanatoside C is a cardiac glycoside, can be used in the treatment of congestive heart failure and cardiac arrhythmia.Lanatoside C has an IC50 of 0.19 μM for dengue virus infection in HuH-7 cells. Lanatoside C can effectively inhibit all four serotypes of dengue virus, flavivirus Kunjin, alphavirus Chikungunya, Sindbis virus and the human enterovirus 71 .
    Lanatoside C
  • HY-P4037

    HCV Infection
    HCV Core Protein (107-114) is a least immunogenic residue of the major linear HCV core regions. HCV Core Protein (107-114) is identified as the binding site within the region 101-118, which contains two residues differing between genotypes Ⅰ/Ⅱ and Ⅲ/Ⅵ. HCV Core Protein (107-114) might be a potential site for dissemination of HCV serotypes .
    HCV Core Protein (107-114)
  • HY-106161S1

    AG7088-d7

    Isotope-Labeled Compounds Enterovirus Virus Protease Infection
    Rupintrivir-d7 is a deuterated labeled Rupintrivir . Rupintrivirvr (AG7088), an antiviral agent, is a potent, selective and irreversible inhibitor of human rhinovirus (HRV) 3C protease. Rupintrivirvr inhibits replication of a panel of 48 different HRV serotypes in H1-HeLA and MRC-5 cell protection assays, with a mean EC50 of 0.023 μM. Rupintrivirvr shows immune-modulatory effect .
    Rupintrivir-d7
  • HY-139602
    (+)-JNJ-A07
    2 Publications Verification

    Flavivirus Dengue virus Virus Protease Infection
    (+)-JNJ-A07 is a highly potent, orally active pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction. (+)-JNJ-A07 exerts nanomolar to picomolar activity against a panel of 21 clinical isolates. (+)-JNJ-A07 has a favourable pharmacokinetic profile that results in outstanding efficacy against dengue virus infection in mouse infection models .
    (+)-JNJ-A07
  • HY-B1030R

    Dengue virus Flavivirus Autophagy Enterovirus Cardiovascular Disease Cancer
    Lanatoside C (Standard) is the analytical standard of Lanatoside C. This product is intended for research and analytical applications. Lanatoside C is a cardiac glycoside, can be used in the treatment of congestive heart failure and cardiac arrhythmia.Lanatoside C has an IC50 of 0.19 μM for dengue virus infection in HuH-7 cells. Lanatoside C can effectively inhibit all four serotypes of dengue virus, flavivirus Kunjin, alphavirus Chikungunya, Sindbis virus and the human enterovirus 71 .
    Lanatoside C (Standard)
  • HY-121663

    Others Infection
    ST-148 is a novel small molecule compound that has potent inhibitory effects against all four dengue virus serotypes. In the nonlethal AG129 mouse dengue virus infection model, ST-148 significantly reduced viremia and viral load in vital organs and tended to reduce plasma cytokine levels. Compound resistance was associated with the dengue virus capsid (C) gene, and the direct interaction of ST-148 with the C protein was presumed to be achieved through the protein's built-in fluorescence change in the presence of the compound. Therefore, ST-148 appears to interact with the dengue virus C protein and inhibit one or more unique steps of the viral replication cycle.
    ST-148
  • HY-D1056
    Lipopolysaccharides, from E. coli O55:B5
    Maximum Cited Publications
    213 Publications Verification

    LPS

    Toll-like Receptor (TLR) Inflammation/Immunology Cancer
    Lipopolysaccharides, from E. coli O55:B5 is an endotoxin extracted from E. coli O55:B5, consisting of an antigen-specific chain, A core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O55:B5 activates TLR-4 of immune cells. Lipopolysaccharides, from E. coli O55:B5 can induce the change of body temperature in rats with dose and serotype specificity. Lipopolysaccharides, from E. coli O55:B5 caused a heterogeneous and dose-independent increase in body temperature in rats .
    Lipopolysaccharides, from E. coli O55:B5
  • HY-D1056A4

    LPS, from Escherichia coli (O128:B12)

    Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from E. coli O128:B12 is commonly used to stimulate the inflammatory pathway in an infection/inflammation induced preterm animal model. Specific Lipopolysaccharides from E. coli serotypes induce activation of different inflammatory pathways in the neonatal rat brain. Compared with other Escherichia coli, Lipopolysaccharides (O111:B4, O55:B5, O127:B8), Lipopolysaccharides, from E. coli O128:B12 has lower induction efficiency of inflammation. Cub survival rate was 100% after the treatment .
    Lipopolysaccharides, from E. coli O128:B12
  • HY-136797

    Others Infection
    BP13944 is a potential small molecule inhibitor discovered by high-throughput screening. It can effectively inhibit the expression of dengue virus (DENV) replicons with an EC50 value of 1.03±0.09 μM. BP13944 can inhibit the replication or viral RNA synthesis of all four serotypes of DENV, but is ineffective against Japanese encephalitis virus. BP13944 may target the DENV NS3 protease, and the E66G amino acid substitution in the NS3 protease region will cause the virus to become resistant to BP13944. BP13944 has no obvious cytotoxicity. As there is currently no effective dengue vaccine and treatment, BP13944, as an effective small molecule inhibitor, may become a potential agent for the treatment of dengue in the future.
    BP13944
  • HY-D1056A2

    LPS, from Escherichia coli (O127:B8)

    Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from E. coli O127:B8 is a lipopolysaccharide endotoxin from E. coli O127:B8 and TLR-4 activator, Activates disease-associated molecular patterns (PAMPs) of the immune system and induces cell secretion of migratory bodies. Lipopolysaccharides, from E. coli O127:B8 consists of an antigen-specific O-chain, A core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O127:B8 can induce changes in body temperature in rats and is dose and serotype specific. High dose of Lipopolysaccharides, from E. coli O127:B8 can cause a double change of body temperature in rats, that is, hypothermia followed by fever. In addition, Lipopolysaccharides, from E. coli O127:B8 can induce inflammation and inhibit reproduction, and can significantly increase the mitotic activity of mollusks .
    Lipopolysaccharides, from E. coli O127:B8

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: